

reported 175 cases of hypomagnesemia associated with prolonged use of proton pump inhibitors (PPI) since its introduction. This alert was published by the FDA in 2011.

OBJECTIVES


Identify hospitalized patients with hypomagnesemia. Look for the relationship between hypomagnesemia and PPI use. Determine the frequency of hypomagnesemia in hospitalized patients with PPI use. Assess the frequency of hypomagnesemia in hospitalized patients with PPI use. Determine the frequency of hypomagnesemia in hospitalized patients with PPI use.

METHODS

Retrospective review of the first half of 2019 of magnesium levels in a geriatric ward of 160 beds.

Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use. Hypomagnesemia associated with chronic PPI use.

magnesium treatment



49 patients (79.03%)

In 12 patients (19.3%) magnesium low levels were observed in 12 of them (9.67%)

We collected 14 patients with hypomagnesemia and 11 (17.74%)

Of the 2301 admitted patients, 1931 were treated with a PPI (85%). Hypomagnesemia by PPI treatment was 1/31 patients.

These results suggest that PPI treatment is associated with hypomagnesemia. Pharm